GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haw Par Corp Ltd (OTCPK:HAWPF) » Definitions » EBIT
中文

Haw Par (Haw Par) EBIT : $172.5 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Haw Par EBIT?

Haw Par's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was $89.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $172.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Haw Par's annualized ROC % for the quarter that ended in Dec. 2023 was 16.12%. Haw Par's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 481.99%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Haw Par's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -23.56%.


Haw Par EBIT Historical Data

The historical data trend for Haw Par's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haw Par EBIT Chart

Haw Par Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 145.35 93.28 85.23 117.99 173.37

Haw Par Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.46 59.17 57.40 83.07 89.42

Competitive Comparison of Haw Par's EBIT

For the Drug Manufacturers - General subindustry, Haw Par's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haw Par's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haw Par's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Haw Par's EV-to-EBIT falls into.



Haw Par EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $172.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haw Par  (OTCPK:HAWPF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Haw Par's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=54.258 * ( 1 - 4.93% )/( (403.542 + 236.553)/ 2 )
=51.5830806/320.0475
=16.12 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2602.478 - 60.178 - ( 2152.768 - max(0, 60.178 - 2198.936+2152.768))
=403.542

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2697.379 - 66.008 - ( 2409.745 - max(0, 66.008 - 2460.826+2409.745))
=236.553

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Haw Par's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=178.84/( ( (36.983 + max(-14.01, 0)) + (37.226 + max(-23.033, 0)) )/ 2 )
=178.84/( ( 36.983 + 37.226 )/ 2 )
=178.84/37.1045
=481.99 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(31.727 + 14.207 + 0.23399999999992) - (60.178 + 0 + 0)
=-14.01

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(28.293 + 14.267 + 0.41499999999996) - (66.008 + 0 + 0)
=-23.033

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Haw Par's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=172.493/-732.027
=-23.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haw Par EBIT Related Terms

Thank you for viewing the detailed overview of Haw Par's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Haw Par (Haw Par) Business Description

Traded in Other Exchanges
Address
401 Commonwealth Drive, No. 03-03 Haw Par Technocentre, Singapore, SGP, 149598
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, and Others segment. The company generates maximum revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates a majority of its revenue from the ASEAN countries.

Haw Par (Haw Par) Headlines

From GuruFocus

Haw Par Stock Is Believed To Be Significantly Overvalued

By GF Value GF Value 03-31-2021

Singapore Based Haw Par Selling at a Discount to NAV

By Holmes Osborne, CFA Holmes Osborne, CFA 07-26-2016

First Eagle Comments on Haw Par

By Holly LaFon Holly LaFon 04-24-2018